Test Price
2,800 AED✅ Home Collection Available
EEF2 Gene Spinocerebellar Ataxia Type 26 (SCA26) Autosomal Dominant Genetic Test in UAE | 2800 AED | DHA-Licensed
Executive Summary & Core Metrics
A definitive molecular diagnostic solution for adult-onset autosomal dominant spinocerebellar ataxia type 26 (SCA26). This Next-Generation Sequencing (NGS) test achieves 99.9% diagnostic sensitivity for coding-region variants in the EEF2 gene, classified per ACMG standards. Processed in an ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139). Logistics include VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. Telephonic post-test clinical guidance by a DHA-licensed Consultant Medical Geneticist is included. Direct insurance billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) assay interrogates the entire coding region of the EEF2 gene to detect pathogenic single-nucleotide variants, insertions, deletions, and copy-number alterations implicated in Spinocerebellar Ataxia Type 26 (SCA26). The test delivers a definitive molecular diagnosis, enabling targeted neurological management, accurate prognosis, and cascade family screening. Results are reported with full ACMG variant classification and clinical interpretation.
| Feature | Our Test (DHA-Accredited) | Closest Alternative (Conventional Lab) |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) – full gene analysis including intronic boundaries | Sanger sequencing of selected exons only |
| Detection Rate | >99.9% for coding and splice-site variants (ACMG classified) | ~85% (misses deep intronic and copy-number variants) |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Pre-test Genetic Counselling | Mandatory, via DHA-licensed Consultant Medical Geneticist (pedigree analysis included) | Often not provided |
| UAE Regulatory Compliance | Full compliance with Federal Law No. 2 of 2019 (ICT Health), Federal Decree-Law No. 45 of 2021 (PDPL), and DHA standards | May lack current DHA/MOHAP accreditation |
Physician Insight & Safety Protocols
"A molecular diagnosis of SCA26 through EEF2 gene sequencing removes the prolonged diagnostic uncertainty that many families face. It provides a clear foundation for neurologists to tailor surveillance, manage symptom progression, and offer informed reproductive counselling. A negative result does not exclude all hereditary ataxias; correlation with brain imaging and neurophysiological assessment remains essential."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
Do not alter, adjust, or stop any prescribed anti-epileptic medications, baclofen, or tremor-modifying agents without direct consultation with your treating neurologist. Sudden changes can precipitate withdrawal symptoms or worsen neurological status.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent; unavailable biological family history for segregation analysis; severe coagulopathy precluding venipuncture.
- Exclusion: Age under 16 years without legal guardian consent (in accordance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability).
- ER Red Flags: Sudden gait deterioration, dysphagia with aspiration risk, acute loss of consciousness – proceed to nearest emergency department immediately.
- ER Red Flags: New-onset seizures or respiratory distress in a known SCA26 patient.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the EEF2 gene test for ataxia?
This NGS-based analysis provides definitive confirmation of SCA26 by identifying pathogenic variants in the EEF2 gene. A positive result ends the diagnostic odyssey for adult-onset progressive cerebellar ataxia, enables precise prognosis, triggers cascade family testing, and avoids unnecessary immunosuppressive or anti-inflammatory therapies that are ineffective for this condition.
2. What sample types are accepted and how is collection arranged?
We accept whole blood collected in an EDTA tube, extracted genomic DNA (minimum 2 µg), or a single blood spot on an FTA card. All samples are collected by our DHA-licensed mobile phlebotomy team at your home or workplace between 8 AM and 11 PM. The specimen is transported under ISO-validated temperature-controlled cold-chain conditions to preserve DNA integrity.
3. How are results reported and what post-test support is available?
The final report classifies all detected variants according to ACMG/AMP guidelines (Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Benign). A 30-minute tele-consultation with our Consultant Medical Geneticist is included to explain the findings and their clinical implications. We also facilitate scheduling a follow-up with your neurologist for immediate integration into your care plan. For support, contact us via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all genetic and health data processing, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health information governance. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and undergoes biannual audit by DHA/MOHAP. All genetic data is encrypted in transit and at rest, stored on GDPR-compliant servers, and never shared with third parties without explicit, written patient consent.
Clinical & Logistical Metadata
| Test Name | EEF2 Gene Spinocerebellar Ataxia Type 26 (SCA26) Autosomal Dominant Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted genomic DNA, or FTA card blood spot |
| Methodology Used | Next-Generation Sequencing (NGS) – full coding region and splice-site analysis |
| ICD-10-CM Code | G11.8 |
| LOINC Code | 21636-9 |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians